Laekna Therapeutics
China - Shanghai
BiotechnologyFocus: Small Molecules targeting cancer and liver diseases
Laekna Therapeutics is a life sciences company focused on Small Molecules targeting cancer and liver diseases.
OncologyGastroenterology
Funding Stage
PUBLIC
Open Jobs
1
Pipeline & Clinical Trials
LAE103 injection
Overweight and ObesityClinical Trials (1)
NCT07230496A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants
Phase 1LAE102 intravenous administration
Overweight and Obese VolunteersClinical Trials (1)
NCT06493084Evaluate LAE102 in Healthy and Overweight/Obese Subjects
Phase 1LAE005 + Afuresertib + Nab-Paclitaxel
Solid TumorClinical Trials (1)
NCT05390710PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
Phase 1LAE102 SC
Postmenopausal[14C]Afuresertib
Healthy VolunteerClinical Trials (1)
NCT05489744Human Mass Balance and Biotransformation Study of [14C]Afuresertib
Phase 1Phase I and Phase II: LAE001/prednisone + afuresertib
Metastatic Castration-resistant Prostate CancerClinical Trials (1)
NCT04060394Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Phase 1/2Afuresertib
Solid TumorClinical Trials (1)
NCT05383482Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT03843918A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
Phase 1/2Paclitaxel
Platinum-resistant Ovarian CancerClinical Trials (1)
NCT04374630Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Phase 2Afuresertib
Breast CancerClinical Trials (1)
NCT04851613Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3Open Jobs (1)
Interview Prep Quick Facts
Portfolio: 9 clinical trials
Open Roles: 1 active job